Evidence map›Paper›PMID 37045996›Full record

ArticleNature medicine2023

Evolutionary characterization of lung adenocarcinoma morphology in TRACERx.

Takahiro Karasaki, David A Moore, Selvaraju Veeriah, Cristina Naceur-Lombardelli, Antonia Toncheva, Neil Magno, Sophia Ward, Maise Al Bakir, Thomas B K Watkins, Kristiana Grigoriadis and 43 more

Open access · hybridAbstract read
In one paragraph

Article in Nature medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
23.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 98 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

53 authors at 20 institutions in 9 countries.

Takahiro Karasaki *Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0001-6863-2360
David A Moore *Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-6296-1312
Selvaraju VeeriahCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Cristina Naceur-LombardelliCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Antonia TonchevaCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Neil MagnoCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Sophia WardCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-6777-5279
Maise Al BakirCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-0846-8332
Thomas B K WatkinsCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Kristiana GrigoriadisCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-8435-0176
Ariana HuebnerCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0001-8009-4999
Mark S HillCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0003-0718-8934
Alexander M FrankellCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-0341-7878
Christopher AbboshCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-8983-1382
Clare PuttickCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Haoran ZhaiCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Francisco Gimeno-ValienteCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Sadegh SaghafiniaCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Nnennaya KanuCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Michelle DietzenCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-6853-7563
Oriol PichCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0002-1956-1882
Emilia L LimCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Carlos Martínez-RuizCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-4817-0565
James R M BlackCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Dhruva BiswasCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0001-9141-5188
Brittany B CampbellCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Claudia LeeCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0003-1715-2265
Emma ColliverCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0002-1497-0740
Katey S S EnfieldCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0002-4551-6073
Sonya HesseyCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0001-9856-424X
Crispin T HileyCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Simone ZaccariaCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0002-5265-7392
Kevin LitchfieldCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Nicolai J BirkbakCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.ORCID http://orcid.org/0000-0003-1613-9587
Elizabeth Larose CadieuxCancer Genomics Laboratory, The Francis Crick Institute, London, UK.
Jonas DemeulemeesterCancer Genomics Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0002-2660-2478
Peter Van LooCancer Genomics Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0003-0292-1949
Prasad S AdusumilliThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-1699-2046
Kay See TanDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Waseem CheemaThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-8000-7493
Francisco Sanchez-VegaDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-2990-4893
David R JonesThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-3318-0146
Natasha RekhtmanDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
William D TravisDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Allan HackshawCancer Research UK & UCL Cancer Trials Centre, London, UK.ORCID http://orcid.org/0000-0002-5570-5070
Teresa MarafiotiDepartment of Cellular Pathology, University College London Hospitals, London, UK.
Roberto SalgadoDepartment of Pathology, ZAS Hospitals, Antwerp, Belgium.ORCID http://orcid.org/0000-0002-1110-3801
John Le QuesneCancer Research UK Beatson Institute, Glasgow, UK.ORCID http://orcid.org/0000-0003-3552-7446
Andrew G NicholsonDepartment of Histopathology, Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, UK.
TRACERx Consortium
Nicholas McGranahanCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK. nicholas.mcgranahan.10@ucl.ac.uk.ORCID http://orcid.org/0000-0001-9537-4045
Charles SwantonCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK. Charles.Swanton@crick.ac.uk.ORCID http://orcid.org/0000-0002-4299-3018
Mariam Jamal-HanjaniCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK. m.jamal-hanjani@ucl.ac.uk.ORCID http://orcid.org/0000-0003-1212-1259
The Francis Crick Institute · GBCancer Research UK · GBLondon Cancer · GBRoyal London Hospital · GBGuy's and St Thomas' NHS Foundation Trust · GBManchester University NHS Foundation Trust · GBUniversity Hospitals of Leicester NHS Trust · GBUniversity Hospitals Birmingham NHS Foundation Trust · GBUniversity of Leicester · GBMemorial Sloan Kettering Cancer Center · USUniversity Hospital Southampton NHS Foundation Trust · GBGolden Jubilee National Hospital · GBUniversity College Hospital · GBUniversity College London · GBAberdeen Royal Infirmary · GBInstitute of Cancer Research · GBUniversity of Manchester · GBAarhus University · DKCancer Research UK Manchester CentreNHS Greater Glasgow and Clyde · GB

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
A phase I/II combination immunotherapy clinical trial: mesothelin-targeted chimeric antigen receptor T cells and checkpoint blockade agent in pleural mesotheliomaR01CA235667 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ADUSUMILLI, PRASAD S. · 2019 to 2024
$3.6M
The EDRN Mesothelioma Biomarker Discovery LaboratoryU01CA214195 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI PASS, HARVEY IRA, YANG, HAINING · 2016 to 2021
$3.5M
BRMS1-mediated suppression of metastases in p53 mutant lung adenocarcinomaR01CA217169 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI JONES, DAVID R · 2018 to 2022
$2.5M
Targeting SNP BRMS1v2 A273V/A273V to reduce metastases in lung adenocarcinomaR01CA240472 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI JONES, DAVID R · 2019 to 2023
$2.4M
Image-guided irreversible electroporation directed CAR T-cell delivery to solid tumorsR01CA236615 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ADUSUMILLI, PRASAD S., SOLOMON, STEPHEN BARNETT · 2018 to 2022
$2.0M
Cancer Research UK 17786Cancer Research UK 21999Cancer Research UK 24956Cancer Research UK 29569Cancer Research UK 30025Cancer Research UK C11496/A17786Cancer Research UK C11496/A30025Cancer Research UK C416/A21999Cancer Research UK C444/A15953Cancer Research UK C69256/A30194Cancer Research UK C7893/A26233Cancer Research UK CTRNBC-2022/100001Cancer Research UK CTUQQR-DEC22/100009Cancer Research UK FC001202Medical Research Council CC2008Medical Research Council CC2041Medical Research Council MR/P014712/1Medical Research Council MR/V033077/1NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA217169NCI NIH HHS R01 CA235667NCI NIH HHS R01 CA236615NCI NIH HHS R01 CA240472NCI NIH HHS U01 CA214195Wellcome Trust 211179/Z/18/ZWellcome Trust FC001169Wellcome Trust FC001202
6 · The paper itself

Abstract

Lung adenocarcinomas (LUADs) display a broad histological spectrum from low-grade lepidic tumors through to mid-grade acinar and papillary and high-grade solid, cribriform and micropapillary tumors. How morphology reflects tumor evolution and disease progression is poorly understood. Whole-exome sequencing data generated from 805 primary tumor regions and 121 paired metastatic samples across 248 LUADs from the TRACERx 421 cohort, together with RNA-sequencing data from 463 primary tumor regions, were integrated with detailed whole-tumor and regional histopathological analysis. Tumors with predominantly high-grade patterns showed increased chromosomal complexity, with higher burden of loss of heterozygosity and subclonal somatic copy number alterations. Individual regions in predominantly high-grade pattern tumors exhibited higher proliferation and lower clonal diversity, potentially reflecting large recent subclonal expansions. Co-occurrence of truncal loss of chromosomes 3p and 3q was enriched in predominantly low-/mid-grade tumors, while purely undifferentiated solid-pattern tumors had a higher frequency of truncal arm or focal 3q gains and SMARCA4 gene alterations compared with mixed-pattern tumors with a solid component, suggesting distinct evolutionary trajectories. Clonal evolution analysis revealed that tumors tend to evolve toward higher-grade patterns. The presence of micropapillary pattern and 'tumor spread through air spaces' were associated with intrathoracic recurrence, in contrast to the presence of solid/cribriform patterns, necrosis and preoperative circulating tumor DNA detection, which were associated with extra-thoracic recurrence. These data provide insights into the relationship between LUAD morphology, the underlying evolutionary genomic landscape, and clinical and anatomical relapse risk.

Indexed as

AdenocarcinomaAdenocarcinoma of LungLung NeoplasmsDisease ProgressionDNA HelicasesHumansNeoplasm Recurrence, LocalNuclear ProteinsTranscription FactorsDNA HelicasesNuclear ProteinsSMARCA4 protein, humanTranscription Factors

Identifiers

PMID37045996
PMCPMC7614478
OpenAlexW4365143778

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.